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INTRODUCTION 
INTRODUCTION
1.1 ORAL DRUG DELIVERY SYSTEMS  
The oral  route  of  drug administration is  the most important  method of  administering
drugs for systemic effects. Oral route has been the most popular for delivery of drugs
because  of convenience  and ease of administration,  greater  flexibility in dosage  form
design and ease of production and low cost of such a system.  It is probable that at least
90% of all drugs used to produce systemic effects are administered by the oral route.
Oral dosage forms: There are mainly two types of oral dosage forms. 
Those are
                              1. Solid oral dosage forms
                              2. Liquid oral dosage forms
Advantages of oral dosage forms:
 Superior flexibility in dosage form design.
 Patient acceptance.
 Safe route of drug administration.
 Minimum potential damage at the site of administration.
 Convenience in administration.
Disadvantages of oral dosage forms:
 Limited solubility of drug.
 Poor permeation across the gastrointestinal tract.
 Oral bioavailability is affected by presystemic metabolism. 
 Drug absorption in the gastro intestinal tract.
1.1.1 Solid oral dosage forms: Of drugs that are administered orally, solid oral dosage
forms  represents  the  preferred  class  of  product.  Tablets  and  capsules  occupies  major
portion of  solid  oral  dosage  forms.   The  reasons for  preference  of  solid  orals are as
follows:
 These  are  less  expensive  compared  to  liquid  orals  because  of  high
manufacturing and shipping costs of liquid orals.
 Drugs are generally more stable both chemically and physically in solid form
than in a liquid form and expiration dates tend to be longer.
 Tablets and capsules represent unit dosage forms in which one usual dose of
the drug has been accurately placed.
Of the two oral solid dosage forms commonly employed in this country, the tablet and the
capsule the tablet has a number of advantages.                                                  
 1.1.2 TABLETS: 
                   The term tablet derived from the Latin word ‘tabuletta’ which is associated
with  the  appearance  of  dosage  form,  i.e.,  tablets  are  small  disc  like  or  cylindrical
specimens. Tablets are defined as unit solid dosage forms containing one or more active
ingredients and prepared either by compression or molding. In addition to medicament(s)
tablet also contains inactive ingredients, usually called as excipients. Tablets are the most
common type of solid dosage form in contemporary use. These are mainly intended for
oral administration. Tablets are used mainly for systemic drug delivery but also for local
drug action. For systemic use the drug must be released from the tablet, i.e., normally
dissolved in the fluids of the mouth, stomach or intestine and thereafter be absorbed into
the systemic circulation, by which it reaches its site of action. Alternatively tablets can be
formulated for local delivery of drugs.
1.1.3 Properties of tablets:
  Accurate  dosage of medicament, uniform in weight, appearance and diameter 
 Have the strength to withstand the rigors of mechanical shocks encountered in
      its production, packaging, shipping and dispensing
 Release the medicinal agents in the body in a predictable and reproducible
    manner. 
 Elegant product, acceptable size and shape.
 Chemical and physical stabilities.
    Advantages of Tablets:
 They are unit dosage form, and they offer greatest capabilities of all oral 
     dosage forms for the greatest dosage precision and the least content variability.
 Their cost is lowest of all the dosage forms.
 They are the lightest and most compact of all the dosage forms.
 Product identification is simplest when employing an embossed punch face.
 They lend themselves to certain special release profile products
 They have the best combined properties of chemical, mechanical, and 
    microbiological stability of all the oral forms
     Disadvantages of the Tablets:
 Some drugs resist compression in to dense compacts, owing to their amorphous
    nature or flocculent, low-density character.
 Drugs with poor wetting, slow dissolution properties, intermediate to large 
    dosages, optimum absorption high in the GIT may be impossible to formulate 
    and manufacture as a tablet.
 Drugs with objectionable organoleptic properties may require coating after 
    compression, which will increase the cost of production.
  
1.1.4 TYPES AND CLASSES OF TABLETS:
A. Oral tablets for ingestion: 
 Compressed tablets
 Multiple Compressed tablets
 Repeat action tablets
 Delayed action and enteric coated tablets
 Sugar coated tablets
 Film coated tablets
 Chewable tablets 
B. Tablets used in the oral cavity:
 Buccal tablets
 Sublingual tablets
 Troches and lozenges
 Dental cones
C. Tablets administered by other routes:
 Implantation tablets
 Vaginal tablets (inserts)
D. Tablets used to prepare solutions:
 Effervescent tablets
 dispensing tablets
 hypodermic tablets
 tablet triturates or molded tablets
1.1.5 TABLETTING METHODS:
  Tabletting methods are categorized into
 Dry  methods   
                     - Dry granulation 
                     - Direct compression
 Wet methods 
                      - Wet granulation 
1.2.1 Dry granulation:
Dry granulation processes create granules by light compaction of the powder blend under
low pressures. The compacts so-formed are broken up gently to produce granules 
(agglomerates). This process is often used when the product to be granulated is sensitive 
to moisture and heat. Dry granulation can be conducted on a tablet press using slugging 
tooling or on a roll press called a roller compactor. Dry granulation equipment offers a 
wide range of pressures to attain proper densification and granule formation. Dry 
granulation is simpler than wet granulation, therefore the cost is reduced. However, dry 
granulation often produces a higher percentage of fine granules, which can compromise 
the quality or create yield problems for the tablet. Dry granulation requires drugs or 
excipients with cohesive properties, and a 'dry binder' may need to be added to the 
formulation to facilitate the formation of granules.
1.2.2 Direct compression: 
In Direct compression tablets are compressed directly from powder blends of the active 
ingredient and suitable excipients. No pretreatment of the powder blends by wet or dry 
granulation procedures is necessary.
1.2.3Wet granulation
Wet granulation is a process of using a liquid binder to lightly agglomerate the powder
mixture. The amount of liquid has to be properly controlled, as over-wetting will cause
the granules to be too hard and under-wetting will cause them to be too soft and friable.
Aqueous solutions have the advantage  of being safer  to deal  with than solvent-based
systems but may not be suitable for drugs which are degraded by hydrolysis.
1.2.4 Procedure
• Step 1: The active ingredient and excipients are weighed and mixed.
• Step 2: The wet granulate is prepared by adding the liquid binder–adhesive to the 
powder blend and mixing thoroughly. Examples of binders/adhesives include 
aqueous preparations of cornstarch, natural gums such as acacia, and cellulose 
derivatives such as methyl cellulose, gelatin and povidone.
• Step 3: Screening the damp mass through a mesh to form pellets or granules.
• Step 4: Drying the granulation. A conventional tray-dryer or fluid-bed dryer are 
most commonly used.
• Step 5: After the granules are dried, they are passed through a screen of smaller 
size than the one used for the wet mass to create granules of uniform size.
           1.3.1 MODIFIED RELEASE PROFILES:
The term modified-release drug product is used to describe products that alter the timing
and/or  the  rate  of  release  of  the  drug  substance.  A  modified-release  dosage  form is
defined "as one for which the drug-release characteristics of time course and/or location
are  chosen  to  accomplish  therapeutic  or  convenience  objectives  not  offered  by
conventional dosage forms such as solutions, ointments, or promptly dissolving dosage
forms as presently recognized".
     Advantages:
 Obtain extended or prolonged release
 Avoid release in the stomach (enteric coating)
 Target different parts of the GI tract (colon delivery)
 Delay release from the stomach
     Disadvantages:
 Release and uptake of the drug can be affected by the passage  through the
gastro- intestinal track
 Only limited periods of sustained release can be achieved this dependence on
where in the GI tract uptake occurs. True sustained release is often difficult to obtain.
Several types of modified-release drug products are recognized.
A. Extended release
 Sustained release
 Controlled release
B. Delayed release
C. Targeted release
 Site specific targeting
 Receptor specific targeting
1.3.2 EXTENDED RELEASE DOSAGE FORMS:
 A dosage form that allows at least a twofold reduction in dosage frequency as compared
to that drug presented as an immediate release form. Ex: Controlled release, Sustained
release.
 a. Controlled release dosage form:  An ideal  controlled release system is the one
which delivers the drug at a predetermined rate, locally or systemically, for a specified
period  of  time.  Thus  unlike  conventional  immediate  release  systems,  the  rate  of
appearance  of  drug  in  the  body  with  such  a  system  is  not  controlled  by  absorption
process. Following absorption of drug from such a system there is no control over its fate.
It differs from sustained release systems which simply prolong the drug release and hence
plasma drug levels for an extended period of time (i.e., not necessarily at a predetermined
rate)
  b. Sustained release dosage form: An ideal sustained release system is the one which
slowly releases  the drug locally  or  systemically,  for  an extended  period  of  time,  not
particularly at a pre determined rate. 
1.3.3 DELAYED RELEASE DOSAGE FORMS:
An ideal delayed release system is the one which releases a discrete portion of drug at a 
time or times other than promptly after administration, although one portion may be 
released promptly after administration. Ex: Enteric coated dosage forms
1.3.4 TARGETTED RELEASE DOSAGE FORMS:
An ideal targeted drug delivery system is the one which delivers the drug only to its site
of action and not to the non targeted organs or tissues. With this approach control of 
kinetics of drug release is difficult.
a. Site  specific  targeting:  This  refers  to  targeting  of  a  drug  directly  to  a  certain
biological location. In this case the target is adjacent to or in the diseased organ or tissue.
b. Receptor targeting: This refers to targeting of a drug directly to a certain biological
location. In this case the target is the particular receptor for a drug within an organ or
tissue. Site specific targeting and receptor targeting systems satisfy the spatial aspect of
drug delivery 
           1.3.5 SUSTAINED RELEASE DOSAGE FORMS:
              The basic goal of any drug therapy is to achieve a steady-state blood or tissue 
level that is therapeutically effective and nontoxic for an extended period of time. The 
design of proper dosage regimen is an important element in accomplishing this goal.
               Sustained release, sustained action, prolonged action, controlled release, 
extended action, timed release, depot and repository dosage forms are terms used to 
identify drug delivery systems that are designed to achieve a prolonged therapeutic effect 
by continuously releasing medication over an extended period of time after 
administration of a single dose.
Advantages:
The several advantages of a sustained drug delivery system over a conventional dosage 
from are-
 Improved patient convenience and compliance due to less frequent drug 
administration.
 Reduction  in  fluctuation  in  steady  levels  and  therefore  better  control  of  disease
condition and reduced intensity of local or systemic side effects.
 Increased safety margin of high potency drugs due to better control of plasma levels.
 Maximum utilization of drug enabling reduction in total amount of dose      
administered.
 Reduction in health care cost though improved therapy release conventional dosage 
forms;  this  may  be  due  to  incomplete  release,  increased  first-pass  metabolism,
increased  instability,  insufficient  residence  time  for  complete  release,
site-specific absorption etc.,
Disadvantages:-   
 Decreased systemic availability in comparison to immediate release conventional   
       dosage forms; this may be due to incomplete release, increased first-pass   
       metabolism, increased instability, insufficient residence time for complete release,  
       site-specific absorption, pH-dependent solubility, etc.
 Poor in vitro-in vivo correlation.
 Possibility of dose dumping due to food, physiologic or formulation variables or  
       chewing or grinding of oral formulations by the patient and thus, increased risk of  
       toxicity.
 Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity  
       reactions.
 Reduced potential for dosage adjustment of drug normally administered in varying 
       strength.
 Higher cost of formulation.
1.3.6 Selection Criteria of Drug:
 Half-life should be 2-8 hours.
 It should not undergo extensive first –pass metabolism.
 It should be stable in GIT.
 Compounds with high partition coefficient are better to choose.
 Lower limit of solubility of a drug is 0.1 mg/ml.
 Drugs absorbed throughout GIT are better candidates.
Fig 1:  Graphical  representation  of  the  coventional  and modified  release  dosage  form
release profiles 
The type of delivery system and route of administration of the drug presented in sustained
drug  delivery  system may depend  upon several  properties  (Bramhankar  and  Jaiswal,
1995). They are
a. Physicochemical Properties of drugs
b. Biological Factors.
c. Route of drug delivery
d. Target sites
e. Acute or chronic dosing
f. The disease
1.4.1 Physicochemical Properties of Drugs
a. Dose size 
For orally administered systems, there is an upper limit to the bulk size of the dose to be
administered. In general a single dose of 0.5 to 1gm is considered maximum (Nicholas et
al., 1987).
         b. Ionization, PKa & Aqueous Solubility 
            The pH Partition hypothesis simply states that the unchanged form of a drug
species  will  be  preferentially  absorbed  through  many  body  tissues.  Therefore  it  is
important to note the relationship between the PKa of the compound and its absorptive
environment. For many compounds, the site of maximum absorption will also be the area
in which the drug is least soluble.
                   For conventional dosage forms the drug can generally fully dissolve in the
stomach and then be absorbed in the alkaline pH of the intestine. For sustained release
formulations much of the drug will arrive in the small intestine in solid form. This means
that the solubility of the drug is likely to change several orders of magnitude during its
release.
 Compounds with very low solubility are inherently controlled, since their release over
the time course of a dosage form in the GIT will be limited by dissolution of the drug.
The lower limit for the solubility of a drug to be formulated in a sustained release system
has been reported to be 0.1mg/ml (Fincher et al., 1968). Thus for slightly soluble drugs,
diffusional systems will be poor choice, since the concentration in solution will be low.
  For example Tetracycline has maximum solubility in the stomach and least solubility in
the  intestine  where  it  is  maximally  absorbed.  Other  examples  of  drugs  whose
incorporation into sustained release systems are limited because of their poor aqueous
solubility and slow dissolution rate are digoxin, warfarrin, griseofulvin and salicylamide.
Very soluble drugs are also good candidates for the sustained release dosage forms. 
c. Partition coefficient    
            The compounds with a relatively high partition coefficient are predominantly lipid
soluble and easily penetrate membranes resulting high bioavailability. Compounds with
very low partition coefficient  will  have difficulty  in  penetrating membranes  resulting
poor bioavailability. Furthermore partitioning effects apply equally to diffusion through
polymer membranes.
           d. Drug Stability
             The drugs, which are unstable in stomach, can be placed in a slowly soluble form
and their release delayed until they reach the small intestine. However, such a strategy
would be detrimental for drugs that either are unstable in the small intestine (or) undergo
extensive gut  wall metabolism, as pointed out in the decrease bioavailability of some
anticholinergic drugs from controlled /sustained release formulation. In general the drugs,
which are unstable in GIT environment poor candidates for oral sustained release forms.
e. Protein Binding
It  is  well  known  that  many  drugs  bind  to  plasma  proteins  with  a  mostly
recirculated  and  not  eliminated.  Drug  protein  binding  can  serve  as  depot  for  drug
producing a prolonged concomitant influence on the duration of drug action. Since blood
proteins are release profile, especially if a high degree of drug binding occurs.
 1.5.1. Biological Factors
a. Biological Half-Life
Therapeutic  compounds  with  half-life  less  than  8  hrs  are  excellent
candidates for sustained release preparations. Drugs with very short half-life (less than 2
hrs)  will  require  excessively  large  amounts  of  drug  in  each  dosage  unit  to  maintain
controlled  effects.  Thus  forcing  the  dosage  form  itself  to  become  too  large  to  be
administered. Compounds with relatively long half-lives, generally greater than 8 hrs are
not used in the sustained release dosage forms, since their effect is already sustained and
also GI transit time is 8-12 hrs (Jantzen et al., 1996). So the drugs, which have long -half
life and short half- life, are poor candidates for sustained release dosage forms.
Some examples of drug with half-lives of less than 2 hours are ampicillin, cephalexin,
cloxacillin, furosemide, levodopa, penicillin G and propylthiouracil.  Examples of those
with  half-lives  of  greater  than  8  hours  are  dicumarol,  diazepam,  digitoxin,  digoxin,
guanethidine, phenytoin and warfarin.
b. Absorption
The characteristics of absorption of a drug can greatly affect its suitability
as a sustained release product. Drugs which are absorbed by specialized transport process
(carrier  mediated)  and  drug  absorption  at  special  sites  of  the  gastrointestinal  tract
(Absorption Window) are poor candidates for sustained release products.
c. Metabolism
 The metabolic conversion of a drug to another chemical form usually can
be considered in the design of a sustained-release system for that drug. As long as the
location,  rate  and  extent  of  metabolism  are  known  and  the  rate  constant(s)  for  the
process (es) are not too large, successful sustained-release products can be developed.
  There  are  two  factors  associated  with  the  metabolism  of  some  drugs;
however that present problems of their use in sustained-release systems. One is the ability
of the drug to induce or inhibit enzyme synthesis; this may result in a fluctuating drug
blood  level  with  chronic  dosing.  The  other  is  a  fluctuating  drug  blood  level  due  to
intestinal (or other tissue) metabolism or through a hepatic first-pass effect.
  Examples  of  drugs  that  are  subject  to  intestinal  metabolism  upon oral
dosing are hydralazine, salicylamide, nitroglycerine,  isoproterenol, chlorpromazine and
levodopa. Examples of drugs that undergo extensive first-pass hepatic metabolism are
propoxyphene, nortriptyline, phenacetine, propranolol and lidocaine.
Drugs that are significantly metabolized especially in the region of the small intestine can
show  decreased  bioavailability  from  slower  releasing  dosage  forms.  This  is  due  to
saturation of intestinal wall enzyme systems. The drugs should not have intestinal first
pass  effect  and  should  not  induce  (or)  inhibit  metabolism  are  good  candidates  for
sustained release dosage form.
1.6. TECHNIQUES FOR PREPARING SUSTAINED RELEASE 
    FORMULATIONS:
1.6.1 Based on drug modification:
       a. Complex formation: The rate of dissolution of solid complex in biological fluids
and rate of dissociation o complex in the solution are considered and they depend upon
PH and composition of gastric and intestinal fluids.
       b. Drug adsorbate preparation: In this product is insoluble. Drug availability is
determined by rate of disabsorption.
       c.  Prodrug  synthesis:  They  are  inactive  and  need  enzymatic  hydrolysis  for
regeneration, Solubility, absorption rate of prodrug must be lower than parent drug.
       d. Ion exchange resins: They are water insoluble, cross linked polymers containing
salt forming groups. The drug is bound to the resin by using chromatographic column or
by prolong contact.  Drug release from this complex depends on PH and property of resin
1.6.2 Based on dosage form modification:
a. Microencapsulation: It is a process in which tiny particles are surrounded by uniform
coating (microcapsule) or held in a matrix polymer (microsphere)
b. Barrier coating: In this one quarter of granules are in non sustained form for sudden
drug release, remaining part are coating for sustained release.
C.Matrix embedding: Drug is dispersed in a matrix of retardant material which may be
encapsulated or compressed in a tablet.
1.6.3 Release Rate and Dose Consideration: 
The conventional  dosage  forms include solutions,  capsules,  tablets,  emulsions,
etc.  These dosage  forms can be considered to release their  active ingredients  into an
absorption pool immediately.
   Kr     Ka                     Ke
             Dosage form                    Absorption pool                         Target area   
 Drug Release                     Absorption                                  Elimination
           
The absorption pool represents a solution of the drug at the site of absorption.
Where
Kr= First order rate constant for drug release.
Ka=First order rate constant for drug absorption.
Ke=First order rate constant for overall drug elimination.
For immediate release dosage forms Kr >>> Ka or alternatively absorption of drug across
a biological membrane is the rate-limiting step in delivery of the drug to its target area.
For non-immediate release dosage forms, Kr  <<< Ka,  that is, release of drug from the
dosage form is the rate limiting step. This cause the above kinetics scheme to reduce to
   
                                Kr                    Ke
       Dosage form                   Target area           
                            Release                             Elimination        
          Thus, the effort to develop a delivery system that releases drug slowly must be
directed primarily at altering the release rate by affecting the value of Kr.
          The ideal goal in designing a controlled-release system is to deliver drug to the
desired site at a rate according to needs of the body, i.e. a self-regulated system based on
feedback control but this is a difficult assignment.
            1.7 BENIGN PROSTATIC HYPERPLASIA (BPH):
Benign prostatic hyperplasia (BPH) also known as  benign prostatic hypertrophy
(technically  a  misnomer),  benign  enlargement  of  the  prostate  (BEP),  and
adenofibromyomatous  hyperplasia,  refers  to  the  increase  in  size  of  the  prostate.  It  is
common for  the prostate  gland  to  become enlarged  as  a  man ages.  Doctors  call  this
condition benign prostatic hyperplasia (BPH), or benign prostatic hypertrophy. 
                                    
                                                Fig 2: Normal urine flow.
As a man matures, the prostate goes through two main periods of growth. The
first occurs early in puberty,  when the prostate doubles in size. At around age 25, the
gland  begins  to  grow again  and  the  Second growth  phase  often results  year  later  in
Benign prostatic hyperplasia (BPH).
Why BPH Occurs:
The cause of BPH is not well understood. No definite information on risk factors
exists. For centuries, it has been known that BPH occurs mainly in older men and that it
doesn't  develop in men whose testes  were  removed before  puberty.  Throughout  their
lives, men produce both testosterone, an important male hormone, and small amounts of
estrogen, a female hormone. 
               As men age, the amount of active testosterone in the blood decreases, leaving a
higher proportion of estrogen. Studies done on animals have suggested that BPH may
occur because the higher amount of estrogen within the gland increases the activity of
substances that promote cell growth.
Another theory focuses on dihydrotestosterone (DHT), a substance derived from
testosterone in the prostate, which may help control its growth. Most animals lose their
ability to produce DHT as they age. However, some research has indicated that even with
a drop in the blood's testosterone level, older men continue to produce and accumulate
high levels of DHT in the prostate. This accumulation of DHT may encourage the growth
of cells. Scientists have also noted that men who do not produce DHT do not develop
BPH.
Symptoms:
 The  symptoms  of  BPH vary,  but  the  most  common ones  involve  changes  or
problems with urination, such as a) a hesitant, interrupted, weak stream b) urgency and
leaking  or  dribbling  c)  more  frequent  urination,  especially  at  night.  The  size  of  the
prostate does not always determine how severe the obstruction or the symptoms will be.
Some men with greatly enlarged glands have little obstruction and few symptoms while
others, whose glands are less enlarged, have more blockage and greater problems.
Treatment:
Men who have BPH with symptoms usually need some kind of treatment at some
time.. The results of their studies indicate that early treatment may not be needed because
the symptoms of BPH clear up without treatment in as many as one-third of all mild
cases. Instead of immediate treatment, they suggest regular checkups to watch for early
problems. If the condition begins to pose a danger to the patient's health or causes a major
inconvenience to him, treatment is usually recommended.
REVIEW OF LITERATURE
2.1 REVIEW OF LITERATURE
T.S.  Nithiyananthan,  et  al.,  (2009) has  performed  “Prolonged,  sustained  or
extended release systems, release the active ingredient slowly than conventional dosage
forms  similarly  administered.  Tamsulosin  is  selective,  potent  and  competitive  α1  –
adrenoreceptor antagonist. It has a greater affinity for the α1A – receptor subtype and is
indicated to treat uretheral stone symptoms associated with benign prostatic hyperplasia.
In the present work, attempt was made to develop and once daily sustained release matrix
tablet  of  Tamsulosin  hydrochloride.  Hydroxy  propyl  methyl  cellulose  was  used  as  a
hydrophilic  matrix  polymer.  The  formulation  showed  acceptable  pharmacotechnical
properties and HPLC assay requirements. 
Tsuda Y, et al., (2010) has performed Population pharmacokinetics of tamsulosin
hydrochloride  in  paediatric  patients  with  neuropathic  and  non-neuropathic  bladder.
Pharmacokinetics  and  Non-Clinical  Safety  Department,  Nippon Boehringer  Ingelheim
Co., Ltd,  Hyogo,  Japan. Tamsulosin is available on prescription as a modified release
capsule in the US (Flomax), and in most European countries for the treatment of the signs
and  symptoms  of  benign  prostatic  hyperplasia  (BPH).  The  pharmacokinetics  of
tamsulosin hydrochloride (Hydrochloric acid) have been extensively studied in adults
 Chang HS, et al., (2009) has performed Assessment of patient-reported outcome
of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
and  treated  with  Tamsulosin  Hydrochloride  in  Korea. To  evaluate  the  effect  of
tamsulosin 0.2 mg once daily in treatment of patients with benign prostatic hyperplasia
(BPH) using the new subjective assessment of patient-reported outcomes and the lower
urinary tract symptoms (LUTS) outcome score (LOS).
 Van  Hoogdalem,  et  al.,  (1997) has  performed Disposition  of  the  selective
alpha1A-adrenoceptor  antagonist  tamsulosin  in  humans:  comparison  with  data  from
interspecies  scaling.  Tamsulosin-Hydrochloric  acid  is  an  alpha1A-adrenoceptor
antagonist that is mainly eliminated by metabolism in animals and humans and is highly
bound to alpha1-acid glycoprotein in blood plasma. The disposition of the compound (0.4
mg as modified-release granules in a capsule) was determined in male volunteers, using
intravenous  (iv)  infusion  of  tamsulosin-Hydrochloric  acid  (0.125  mg  over  4  h)  as
reference treatment for the assessment of absolute oral bioavailability. 
Nieminen T, et al., (2005) has performed Effects of adrenoceptor blocking drugs
on  cardiovascular  responsiveness  to  passive  orthostasis:  a  placebo-controlled  double-
blind study. To compare the acute effects of the beta-blocker propranolol (CAS 525-66-
6), beta + alpha1-blocker carvedilol (CAS 72956-09-3) and alpha1-blocker tamsulosin
(CAS 106463-17-6) on the cardiovascular responses to passive orthostasis.
Prosnitz  RG,  et  al.,(1999)   has  performed, Tamsulosin  palliates  radiation-
induced urethritis in patients with prostate cancer: results of a pilot study. A pilot study
was performed to determine the effectiveness of Flomax (Tamsulosin Hydrochloride) in
the  management  of  acute  radiation  urethritis  in  prostate  cancer  patients  undergoing
conformal  external  beam  radiation  therapy  (RT).  Potential  predictors  of  response  to
Flomax were evaluated.
Sudoh K,  et al.,  (1996) has performed Effect  of tamsulosin,  a novel alpha 1-
adrenoceptor antagonist, on urethral pressure profile in anaesthetized dogs. The effect of
tamsulosin(YM617,(R)(-)-S-[2-[[2-(o-ethoxyphenoxy)ethyl]amino]propyl]-2-
methoxybenzenesulfonamide  Hydrochloric  acid),  a  potent  and  selective  alpha  1-
adrenoceptor  antagonist,  was  examined  on  urethral  pressure  profile  (UPP)  and  mean
arterial blood pressure (MBP) in pentobarbital anaesthetized male dogs. 
Ozkan  SA,  et  al.,  (2003) has  performed   Voltammetric  investigation  of
TamsulosinThe  electrooxidative  behavior  and  determination  of  Tamsulosin
Hydrochloride (TAM), one of the alpha (1) -adrenoceptor antagonist, on a glassy carbon
disc  electrode  were  investigated  for  the  first  time  by  using  cyclic,  linear  sweep,
differential  pulse  (DPV)  and  square  wave  voltammetry  (SWV).  TAM  showed  an
irreversible oxidation behavior at all pH values and buffers studied
  García-Sáinz, et al., (1996)  has performed  Coexpression of alpha 1A- and alpha
1B-adrenoceptors  in  the  liver  of  the  rhesus  monkey  (Macaca  mulatta).The  alpha  1-
adrenoceptors  present  in  the  liver  of  rhesus  monkeys  was  characterized  using
[3H]prazosin. This radioligand binds to monkey liver membranes with high affinity (KD
0.33 nm) to a moderately abundant number of sites (97 fmol/mg of protein). These sites
were characterized pharmacologically,  by binding competition, observing two affinities
for most ligands. These data strongly suggest that Macaca mulatta liver cells coexpress
alpha 1A- and alpha 1B-adrenoceptors. Expression of the mRNA for these receptors was
confirmed by reverse transcriptase-polymerase chain reactions.
 Jeong-Soo  KIM,  et  al.,  (2007  ) has  performed  “Statistical  Optimization  of
Tamsulosin Hydrochloride Controlled Release Pellets Coated with the Blend of HPMCP
and HPMC” The objective of the present study was to evaluate three coating parameters
for  the  application  of  a  blend  of  HPMCP  and  HPMC  in  ethylcellulose   aqueous
dispersions  (Surelease®)  in  order  to  obtain  controlled  release  of   tamsulosin
hydrochloride.. In addition, the dissolution profiles of the controlled release pellets coated
with the optimized formulation were similar to those of the commercial Product.
 Min-Soo Kima, et al., (2007) has performed,” Development and optimization of
a  novel  oral  controlled  delivery  systemfor  tamsulosin  hydrochloride  using  response
surface  methodology”  The  purpose  of  this  study  was  to  develop  and  optimize  oral
controlled-release formulations for tamsulosin hydrochloride using a combination of two
cellulose ester derivatives, hydroxypropyl  methylcellulose (HPMC) and hydroxypropyl
methylcellulose  phthalate  (HPMCP),  with  Surelease®as  a  coating  material.  A  three-
factor,  three-level  Box-Behnken  design  was  used  to  prepare  systematic  model
formulations.  The  response  surface  methodology  (RSM)  and  multiple  response
optimizations  utilizing  the  polynomial  equation  were  used  to  search  for  the  optimal
coating formulation
Masaki Ando (2006) et al has performed, . “Development and evaluation of a
novel  dry-coated  tablet  technology  for  pellets  as  a  substitute  for  the  conventional
encapsulation technology” Pellet formulations as represented by multiparticulate systems
are  often  contained in  hard  capsules.  OSDRC-technology  employs  a  double-structure
punch (center punch and outer punch) allowing for dry-coated tablets to be assembled in
a single run. The results revealed that thinner outer punches are not always better for
filling small tablets with large amounts of pellets..We considered this to be due to the
friction  between  the  pellets  and  punch  wall.  We  concluded  that  OSDRC-technology
could  be  applied  to  capsule-like  forms  containing  pellets  _50  wt%  through  an
unconventional approach.
 Boyapally  H,  et al.,  (2009), Developed  and  release  mechanism of  diltiazem
Hydrochloric acid prolonged release matrix tablets using HPMC and cocluded that  the
developed drug delivery system provided prolonged drug release rates over a defined
period of time. DIL tablets prepared using dry mixing and direct compression and the
core consisted of hydrophilic and hydrophobic polymers such as hydroxyl propyl methyl
cellulose (HPMC) and eudragits RLPO.
 Hiremath  PS, et  al.,  (2008), developed  oral  controlled  release  matrix  tablet
formulations of isoniazid using hydroxypropyl  methylcellulose and confirmed that the
release rate of the drug from the HPMC matrices is highly influenced by the drug/HPMC
ratio and viscosity grade of the HPMC. Also, the effect of compression force and release
media was found to be significant on the release profiles of isoniazid from HPMC matrix
tablets. The release mechanism was found to be anomalous non-Fickian diffusion in all
the cases. The formulations were found to be stable and reproducible.  
Meyyanathan  SN,  et  al.,(2007) Formulated  and  evaluated  dextromethorphan
hydrobromide sustained release tablets  by wet granulation using hydroxypropyl methyl
cellulose  (HPMC-K-100  CR)  The  studies  indicated  that  the  drug  release  can  be
modulated by varying the concentration of the polymer and the fillers. A complete cross-
over bioavailability study of the optimized formulation of the developed sustained tablets
and marketed immediate release tablets was performed on six healthy male volunteers.
The extent of absorption of drug from the SR tablets was significantly higher than that for
the marketed dextromethorphan hydrobromide tablet because of lower elimination rate
and longer half-life.
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3. SCOPE, OBJECTIVE, AND PLAN OF WORK
3.1 SCOPE:
Tamsulosin Hydrochloride is primarily used for benign prostatic hyperplasia, but
is sometimes used for the passage of kidney stones by the same mechanism of smooth
muscle relaxation via alpha antagonism. Benign prostatic hyperplasia (BPH) also known
as  benign  prostatic  hypertrophy  or  benign  enlargement  of  the  prostate  (BEP),  and
adenofibromyomatous hyperplasia, refers to the increase in size of the prostate in middle-
aged and elderly men. Tamsulosin Hydrochloride capsules and tablets are available in
market in the form of sustained release dosage form. Further the sustained release tablet
formulation  in  Europe  and  Japan  markets  are  available  as  patented  OCAS  (Oral
Controlled  Absorption  System)  dosage  form.  The  patent  of  OCAS  is  claiming  an
advantage of absorption of drug in the colon part of GIT, by extending the drug release
more than 24 hours, without having any food effect against the available capsule form
which releases the drug within 12 hrs. Further due to the concerns  with the usage of
different  polymer  matrices  which  were  covered  in  valid  patents  on  formulation  of
Tamsulosin  Hydrochloride  sustained  release  dosage  form; the  requirement  of
identification of a Non-Infringing route was forced. Hence our scope of the current work
is to prepare a Matrix formulation of Tamsulosin Hydrochloride sustained release tablets
which will not  infringe any valid patents and match to the reference product  In-vitro
release profile.  
3.2. OBJECTIVE
The objective of the present study is to:
 To Formulate Tamsulosin Hydrochloride sustained release matrix tablets 
which is Non-Infringing to available sustained release dosage form in the 
market.
 To compare formulated tablets with marketed tablets.
 Evaluation of the formulated product.
 Decrease the cost of dosage form as compared to marketed products.
 Provide a better control of plasma drug levels for greater efficacy and safety.
 To improve patient compliance.
 A greater selectivity of pharmacological activity.
3.3. PLAN OF WORK
 Literature survey
 Reference product evaluation
 Preformulation studies
 Drug and Excipients compatibility studies.
 Process selection.
 Formulation of Tamsulosin Hydrochloride sustained release matrix tablets
 Evaluation of tablets
 Stability Evaluation
MATERIALS AND METHODS
 4.1 MATERIALS
Table 1: Chemicals used
S.No Ingredients Manufacturer Category
1 Tamsulosin  Hydrochloride Rachem pharma ltd
Alpha blocker in
treatment of BPH
2
Dibasic calcium phosphate 
dihydrate (Di-TAB)
Innophos Diluent
3
Amino Methacrylate copolymer
Type- A (Eudragit RL PO)
Evonik Degussa Polymer
4
Methacrylic acid copolymer 
Type-A (Eudragit L100)
Evonik Degussa Polymer
5
Hydrogenated vegetable Oil 
(Lubritab)
JRS pharma Polymer
6 PVPK-30 (Povidone) ISP Binder
7 PEG 20000 Clariant Inc, USA Polymer
8 Stearic acid BASF, Germany Lubricant
9 Magnesium stearate Ferro Lubricant
10 Iso propyl alcohol Rachem Solvent
11 Opadry white Colorcon Coating material
12 Purified water Rachem Solvent
4.2 INSTRUMENTS USED
Table 2: Instruments used
S.No Ingredients Manufacturer Category
1. Weighing balance Sartorius CP225D
2. Analytical  balance Essae DS-852 DS-852
3. Tray dryer Millennium equipments Pvt Ltd METD-6G
4. Tablet compression machine Rimek(karnavathi) D tooling
5. Friabilator Electrolab EF-2(USP)
6. Hardness tester Electrolab EH01
7. Dissolution test system Electrolab TDT-14L
8. Mechanical stirrer Vision labs NA
9. HPLC Schimadzu LC2010CHT
4.3 DRUG PROFILE
Tamsulosin Hydrochloride is primarily used for benign prostatic hyperplasia, but
is sometimes used for the passage of kidney stones by the same mechanism of smooth
muscle relaxation via alpha antagonism. Benign prostatic hyperplasia (BPH) also known
as  benign  prostatic  hypertrophy  or  benign  enlargement  of  the  prostate  (BEP),  and
adenofibromyomatous hyperplasia, refers to the increase in size of the prostate in middle-
aged and elderly men. 
Generic Name                        : Tamsulosin Hydrochloride
Synonyms                               : Tamsulosin
            Chemical name                      : (-)-(R)-5-[2-[[2-Ethoxyphenoxy)ethyl]amino]propyl]-    
                                                   2- Methoxybenzenesulfonamide monohydrochloride
Drug Class                              : Selective Alpha-1 Adrenergic blocking agents.
Molecular weight                   : 444.98
Molecular formula                 : C20H28N2O5S •Hydrochloric acid
Chemical structure               :
                                                     
Description                          : Tamsulosin Hydrochloride is a white crystalline powder.
Solubility                           : It is sparingly soluble in water and methanol, slightly 
                                             soluble in glacial acetic acid and ethanol and practically 
                                                insoluble in ether.
Melting point                    :   Melts with decomposition at approximately at 2300C
Route of administration   :   Oral
Oral dose                               :   0.4mg
BCS Classification               :   Class I (High solubility- High permeability)
Bioavailability                      :   100% oral                                 
Protein  Binding
:   94–99%
(mainly  to  α1-
acid glycoprotein)
Time to peak concentration : 4 to 5 hours under fasting conditions
DESCRIPTION:  Tamsulosin  is  a  selective  antagonist  at  alpha-1A  and  alpha-1B-
adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At
Half life                                :   9-13 hrs in healthy individual
                                                    14-15hrs in patients with BPH
least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-
1B  and  alpha-1D;  their  distribution  differs  between  human  organs  and  tissue.
Approximately  70%  of  the  alpha1-receptors  in  human  prostate  are  of  the  alpha-1A
subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder
neck and prostate.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION:
Tamsulosin,  a  highly  selective  alpha-1A  adrenergic  antagonist.Alpha-1
adrenoceptor  subtypes  are  Alpha-1A,  Alpha-1B  and  Alpha-1D.  The  messenger  RNA
expressionof Alpha-1A,Alpha-1D subtypes are predominant in the prostate and in the base
and neck of the urinary bladder.
Post synaptic alpha 1A blockade leads to:
 Smooth muscle relaxation of prostate, bladder neck and the urethra.  Alpha blocker
improves the dynamic component of subvesical  obstruction due to benign prostatic
hyperplasia.
 Resulting in decreased urinary outflow resistance.
PHARMACOKINETICS:
Absorption
Tamsulosin is well absorbed after  oral  administration under fasting conditions.
Tamsulosin Hydrochloride exhibits linear kinetics following single and multiple dosing,
with achievement of steady state concentrations by the fifth day of once-a-day dosing.
Food    
Food  delays  time  to  peak  plasma  concentration  by  about  2  hours.  When
administered under fasting conditions, bioavailability and peak plasma concentration are
increased by 30 and 40–70%, respectively, compared with fed state.
Distribution
Appears to distribute into extracellular fluids in humans. In animals, distributed
into  kidney,  prostate,  liver,  gallbladder,  heart,  aorta,  and  brown  fat,  with  minimal
distribution into brain, spinal cord, and testes.
Tamsulosin  hydrochloride  is  extensively  bound  to  plasma  proteins  (94%-
99%),primarily alpha 1 acid glycoprotein, with linear binding over a wide concentration
range.
Metabolism:
Tamsulosin  Hydrochloride  is  extensively  metabolised  by  cytochrome  p450
enzymes  in  the  liver.  It  is  indicated  that  CYP3A4  and  CYP2D6are  involved  in
metabolism of tamsulosin. The metabolites undergo extensive conjugation to glucoronide
or sulphate prior to renal excretion.
Elimination:
 Excreted in urine (76%) and feces (21%).
 Tamsulosin Hydrochloride undergoes restrictive clearance in humans via relatively
low systemic clearance.
INDICATIONS AND DOSAGE:
Tamsulosin is indicated for the alleviation of urinary symptoms in men including
a  weak  or  interrupted  urinary stream,  a  feeling that  one  cannot  empty one’s  bladder
completely, urinary hesitancy, urinary frequency, especially at night and urinary urgency,
due to benign prostatic hyperplasia or an enlargement of the prostate.
Dosage:
The recommended dose is 0.4 mg once daily 30 minutes after the same meal each 
day. If a patient fails to respond within 2-4 weeks after initiation of treatment at 0.4 
mg/day the dose may be increased to 0.8 mg/day. 
If administration is interrupted for several days of therapy the patient should be
restarted at 0.4 mg regardless of the dosage they were receiving prior to the interruption.
Usage:
Tamsulosin  Hydrochloride  is  indicated  for  the  treatment  of  “BENIGN
PROSTATIC HYPERPLASIA”.
Reduction  of  urinary  obstruction  and  relief  of  associated  manifestations  in
Hypertensive patients with symptomatic BPH.  Although drug therapy usually is not as
effective as surgical therapy, it may provide adequate symptomatic relief with fewer and
less serious adverse effects compared to surgery.
Precautions:
 Carcinoma of the prostate
 Intraoperative floppy iris syndrome
 Sulfa allergy
 Drug-drug interactions (cimetidine, warfarin, other alpha 1 blockers)
 Pregnancy category B
 Children – currently not sufficient evidence to support use in children
Contraindications:
Urological contraindications:
 Chronic urinary retention with renal failure
 Recurrent heamaturia due to prostatic enlargement
 Recurrent infections and bladder stones.
Cardiac contraindications:
 Hypertension, Mechanical Heart failure, Congestive heart failure.
Other contraindications:
 Cataract surgery, as this cause an intraoperative floppy iris syndrome.
B. DRUG INTERACTIONS:
Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6.
Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in an
increase  in  the  Cmax  and  AUC  of  tamsulosin  by  a  factor  of  2.2  and  2.8
Concomitant treatment with paroxetine (a  strong inhibitor of CYP2D6) resulted in an
increase in the Cmax and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively.
The  effects  of  concomitant  administration  of  a  moderate  CYP2D6  inhibitor  (e.g.,
terbinafine)  on  the  pharmacokinetics  of  Tamsulosin  Hydrochloride have  not  been
evaluated 
The effects of co-administration of both a CYP3A4 and a CYP2D6 inhibitor with 
Tamsulosin Hydrochloride tablets have not been evaluated. 
Cimetidine:
Treatment  with  cimetidine  resulted  in  a  significant  decrease  (26%)  in  the
clearance  of  tamsulosin  hydrochloride,  which  resulted  in  a  moderate  increase  in
Tamsulosin Hydrochloride AUC (44%) 
C. Other Alpha Adrenergic Blocking Agents
The  pharmacokinetic  and  pharmacodynamic  interactions  between  Tamsulosin
Hydrochloride  and other  alpha adrenergic  blocking agents  have not been determined;
however,  interactions  between  Tamsulosin  Hydrochloride  and  other  alpha  adrenergic
blocking agents may be expected.
D. PDE5 Inhibitors
Caution is advised when alpha adrenergic blocking agents including Tamsulosin
Hydrochloride are co-administered with PDE5 inhibitors. Alpha adrenergic blockers and
PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of
these two drug classes can potentially cause symptomatic hypotension.
E. Warfarin
A definitive drug-drug interaction study between Tamsulosin Hydrochloride and
warfarin  was  not  conducted.  Results  from  limited in  vitro and in  vivo studies  are
inconclusive. 
F. Nifedipine, Atenolol, Enalapril
Dosage  adjustments  are  not  necessary  when  Tamsulosin  Hydrochloride  is
administered concomitantly with nifedipine, atenolol, or enalapril.
G. Digoxin and Theophylline
Dosage  adjustments  are  not  necessary  when  a  Tamsulosin  Hydrochloride  is
administered concomitantly with digoxin or theophylline.
            
4.4 EXCIPIENTS PROFILE
4.4.1Eudragit RLPO:
  Synonyms
Polymeric methacrylates.
Description
Fine white powder with slightly amine-like odor.
Structural Formula
   
    
Chemical Name
           Poly (ethyl acrylate, methyl methacrylate, trimethylammonioethylmethacrylate     
Functional categories
          Polymer for developing sustained release matrix tablets and sustaining films.
Density 
          0.390 g/cm3 (bulk)             
 Incompatibilities:  Coagulation may be caused by soluble electrolytes, pH changes, 
some organic solvents and extremes of temperature. 
Stability and storage
           Dry powder polymer forms are stable at temperatures less than 30°C and should
be stored in a tightly closed container at less than 30°C.
4.4.2 Eudragit L100:
Non proprietary names:                                                                                                      
BP : Methacrylic acid ethyl acrylate copolymer (1 : 1)
USPNF : Ammonio methacrylate copolymer
    Methacrylic acid copolymer
Synonyms: 
          Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit;  Kollicoat MAE 30 D; 
Kollicoat MAE 30 DP; polymeric methacrylates.
Chemical name and CAS registry no. :
           Poly(methacrylic acid, methyl methacrylate) 1 : 1 ;  [25806-15-1]
Empirical formulae and molecular weight:
Methacrylic acid–ethyl acrylatecopolymer (1 : 1) is a copolymer of methacrylic
acid and ethylacrylate having a mean relative molecular mass of abou250 000. The ratio
of carboxylic groups to ester groups is about1 : 1. It may contain suitable surfactants such
as sodium dodecylsulfate or polysorbate 80.  The ratio of carboxylic acid to ester groups
is about 1 : 1. 
Functional category:
Eudragit L 100-55 is an alternative to Eudragit L 30 D-55 which is used as an
enteric coating film former for solid-dosage forms. The coating is resistant to gastric juice
but dissolves  readily at  above pH 5.5.  It  is  commercially available as  a  redispersible
powder Acryl-EZE and Acryl-EZE MP which are designed for enteric coating of tablets
and beads, respectively.  Eastacryl 30 D, Kollicoat MAE 30 D, and Kollicoat MAE 30
DP, are aqueous dispersions of methacrylic acid–ethyl acrylate copolymers. They are also
used as enteric coatings for solid-dosage forms.
Description: 
       Several different types of eudragit L100 are commercially available and may be
obtained as the dry powder, as an aqueous dispersion, or as an organic solution. A (60:
40) mixture of acetone and propan-2-ol is most commonly used as the organic solvent.
Eudragit L-100 and Eudragit S-100 are white free-flowing powders with at least 95% of
dry polymers.
Typical properties:   
 Acid value: 300-330
 Alkali value: 23.9-32.3
 Density (bulk): 0.390 g/cm3
 Density (tapped):  0.424g/cm3
 Solubility: soluble in acetone and alcohols and in intestinal fluids from PH 6
 Viscosity (dynamic): 100-200 mpas
Stability and storage conditions: 
Dry powder polymer forms are stable at temperatures less than 30ºC. Above this
temperature, powders tend to form clumps. Dry powders are stable for at least 3 years if
stored in a tightly closed container at less than 30 ºC.  Dispersions should  be stored at
temperatures between 5 and 25 ºC.
Incompatibility: 
Coagulation may be caused by soluble electrolytes,  pH changes,  some organic
solvents, and extremes of temperature.  Dispersions of Eudragit L 30 D, RL 30 D, L 100-
55, and RS 30 D are incompatible with magnesium stearate.
Safety: 
Polymethacrylate  copolymers  are widely used as film-coating materials  in oral
pharmaceutical formulations. They are also used in topical formulations and are generally
regarded as nontoxic and nonirritant materials. A daily intake of 2 mg/kg body-weight of
Eudragit L100 may be regarded as essentially safe in humans.
Applications: 
 Eudragit L, S and FS types are used as enteric coating agents because they are
resistant  to gastric fluid. Different  types  are available that  are soluble at different  pH
values: e.g. Eudragit L is soluble at pH > 6;  Eudragit L 30  D-55 is used as an enteric
coating film former for solid-dosage forms.
4.4.3. Di Calcium Phosphate Di Hydrate:
     Nonproprietary Names:
        BP: Calcium hydrogen phosphate
        USP: Dibasic calcium phosphate
     Chemical Name and CAS Registry Number:
                         Dibasic calcium phosphate dihydrate [7789-77-7]
Empirical Formula and Molecular Weight
                         CaHPO4. 2H2O - 172.09
Category:
                  Tablet and capsule diluents
Synonym:
                  Di- TAB
Description:   
                    It is a white, odorless, tasteless powder or crystalline solid. Tablets produced
with Di-calcium phosphate do not disintegrate readily.
 Properties: 
     Angle of Repose:     28°.3´
     Bulk density: 0.87 gm/cm2
        Tapped density: 0.93 gm/cm2
 Solubility: 
                      Practically insoluble in water
Stability and Storage:
 It  is  a  non-hygroscopic,  relatively  stable  material.  Stored  in  a  well-closed
container, cool, dry place.
Incompatibility:
             It is incompatible with tetracycline antibiotics, Indomethacin
 Applications:  
         Dibasic calcium phosphate dihydrate is widely used in tablet formulations both as 
an excipient and as a source of calcium and phosphorus in nutritional supplements.  
It is one of the more widely used materials, particularly in the nutritional/health 
food sectors.
 It is also used in pharmaceutical products because of its compaction properties, 
and the good flow properties of the coarse-grade material. 
 Dibasic calcium phosphate dihydrate is abrasive and a lubricant is required for 
tableting, for example about 1% w/w of magnesium stearate or about 1% w/w of sodium 
stearyl fumarate is commonly used.
 Two main particle-size grades of dibasic calcium phosphate dihydrate are used in 
the pharmaceutical industry. 
The milled material is typically used in wet-granulated, roller-compacted or 
slugged formulations. 
The ‘unmilled’ or coarse-grade material is typically used in direct-compression 
formulations. Dibasic calcium phosphate dihydrate is non hygroscopic and stable at room
temperature. However, under certain conditions of temperature and humidity, it can lose 
water of crystallization below 100°C. 
Dibasic calcium phosphate dihydrate is also used in toothpaste and dentifrice 
formulations for its abrasive properties.
          4.4.4. Lubritab:
Non proprietary names:   
          BP : Hydrogenated vegetable oil
          JP : Hydrogenated oil
          USPNF : Hydrogenated vegetable oil
Synonyms:
             Hydrogenated cottonseed oil: Akofine; Lubritab; Sterotex.
             Hydrogenated palm oil: Softisan 154.
             Hydrogenated soybean oil: Lipovol HS-K; Sterotex HM
Chemical name and CAS registry no:
            Hydrogenated vegetable oil [68334-00-9]
Empirical formulae:
                 R1COOCH2—CH(OOCR2)—CH2OOCR3
                 where R1, R2, and R3 are mainly C15 and C17.
Functional category:
               Tablet and capsule lubricant; tablet binder
Description: 
               Hydrogenated vegetable oil is a mixture of triglycerides of fatty acids. The two 
types that are defined in the USPNF 23 are characterized by their physical properties; 
Hydrogenated vegetable oil type I occurs in various forms, e.g. fine powder, flakes, or 
pellets. The color of the material depends on the manufacturing process and the form. In 
general, the material is white to yellowish-white with the powder grades appearing more 
white-colored than the coarser grades.
Typical properties:
Density (tapped): 0.57 g/cm3 
Melting point: 61–66°C 
Particle size distribution: 85% < 177 mm, 25% < 74 mm in size
Average particle size is 104 mm.
Solubility: soluble in chloroform, petroleum spirit, and hot propan-2-ol; practically 
insoluble in water.
Stability and Storage Conditions:
Hydrogenated vegetable oil type I is a stable material; typically it is assigned a 2-
year shelf-life. The bulk material should be stored in a well-closed container in a cool,
dry place.
Incompatibilities: 
                     Incompatible with strong oxidizing agents.
Safety:
         Hydrogenated vegetable oil type I is used in food products and oral pharmaceutical
formulations and is generally regarded as a nontoxic and nonirritant excipient. 
Applications: 
 Hydrogenated vegetable oil type 1 is used as a lubricant in tablet and capsule 
formulations. It is used at concentrations of 1–6% w/w, usually in combination with
talc. 
 It may also be used as an auxiliary binder in tablet formulations.
 Hydrogenated vegetable oil type I is additionally used as the matrix-forming 
material in lipophilic-based controlled-release formulations; 
 It may also be used as a coating aid in controlled-release formulations.
 Hydrogenated vegetable oil type I is used as a viscosity modifier in the preparation 
of oil-based liquid and semisolid formulations
 In the preparation of suppositories, to reduce the sedimentation of suspended 
components and to improve the solidification process
In the formulation of liquid and semisolid fills for hard gelatin capsules. 
4.4.5. Stearic Acid:
Nonproprietary Names
BP : Stearic acid
JP : Stearic acid
PhEur : Acidum stearicum
USPNF : Stearic acid
Synonyms
Cetylacetic  acid;  Crodacid;  E570; Edenor;  Emersol;  Hystrene;  Industrene;  Kortacid
1895; Pearl Steric; Pristerene; stereophonic acid; Tegostearic.
Chemical Name and CAS Registry Number
Octadecanoic acid [57-11-4]
Empirical Formula and Molecular Weight
C18H36O2 284.47 (for pure material)
The  USPNF  23  describe  stearic  acid  as  a  mixture  of  stearic  acid  (C18H36O2)  and
palmitic acid (C16H32O2). In the USPNF 23, the content of stearic acid is not less than 40.0%
and  the  sum  of  the  two  acids  is  not  less  than  90.0%.  The  USPNF  23  also  contains  a
monograph  for  purified  stearic  acid;  see  Section  17.  The  PhEur  2005  contains  a  single
monograph for stearic acid but defines stearic acid 50, stearic acid 70, and stearic acid 95 as
containing specific amounts of stearic acid (C18H36O2); 
Functional Category: Emulsifying agent; solubilizing agent; tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology
Stearic  acid  is  widely  used  in  oral  and  topical  pharmaceutical  formulations.  It  is
mainly used in oral formulations as a tablet and capsule lubricant; although it may also be
used as a binder or in combination with shellac as a tablet coating. It has also been suggested
that  stearic  acid  may be used  as  a  sustained-release  drug  carrier.  In  topical  formulations,
stearic acid is used as an emulsifying and solubilizing agent. When partially neutralized with
alkalis  or  triethanolamine,  stearic  acid  is  used in the preparation  of  creams.  The partially
neutralized stearic acid forms a creamy base when mixed with 5–15 times its own weight of
aqueous liquid; the appearance and plasticity of the cream being determined by the proportion
of alkali used. Stearic acid is used as the hardening agent in glycerin suppositories. Stearic
acid is also widely used in cosmetics and food products.
Description
Stearic acid is a hard, white or faintly yellow-colored, somewhat glossy, crystalline solid
or a white or yellowish white powder. It has a slight odor and taste suggesting tallow. 
Stability and Storage Conditions 
Stearic  acid  is  a  stable material.  The bulk material  should be stored in a  well-closed
container in a cool, dry place. 
Incompatibilities
Stearic acid is incompatible with most metal hydroxides and may be incompatible with
oxidizing agents. Insoluble stearates are formed with many metals; ointment bases made with
stearic  acid  may show evidence of  drying  out  or  lumpiness  due to  such a reaction when
compounded with zinc or calcium salts. A number of differential scanning calorimetry studies
have  investigated  the  compatibility  of  stearic  acid  with  drugs.  Although  such  laboratory
studies  have  suggested  incompatibilities,  e.g.  with  naproxen,  they may not  necessarily  be
applicable to formulated products. Stearic acid has been reported to cause pitting in the film
coating of tablets coated using an aqueous film-coating technique; the pitting was found to be
a function of the melting point of the stearic acid.
Safety
Stearic acid is widely used in oral and topical pharmaceutical formulations; it is also used
in  cosmetics  and  food  products.  Stearic  acid  is  generally  regarded  as  a  nontoxic  and
nonirritant material. However, consumption of excessive amounts may be harmful.
LD50 (mouse, IV) : 23 mg/kg
LD50 (rat, IV) : 21.5 mg/kg
4.4.6 Polyethylene Glycol
Nonproprietary Names
BP :  Macrogols
JP :  Macrogol 400
   Macrogol 1500
   Macrogol 4000
          Macrogol 6000
   Macrogol 20000
Ph. Eur : Macrogols
USPNF : Polyethylene glycol
Synonyms
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; polyoxyethylene glycol.
Chemical Name and CAS Registry Number
a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) [25322-68-3]
Empirical Formula and Molecular Weight
HOCH2(CH2OCH2)mCH2OH where m represents the average number of oxyethylene groups.
Alternatively, the general formula
Structural Formula
Functional Category
Ointment base; plasticizer; solvent; suppository base; tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology
Polyethylene  glycols  (PEGs)  are  widely  used  in  a  variety  of  pharmaceutical
formulations including parenteral,  topical,  ophthalmic,  oral,  and rectal  preparations.  It  has
been  used  experimentally  in  biodegradable  polymeric  matrices  used  in  controlled-release
systems.Polyethylene glycols are stable, hydrophilic substances that are essentially nonirritant
to the skin.  They do not readily penetrate  the skin,  although the polyethylene  glycols are
water-soluble  and  are  easily  removed  from the  skin  by  washing,  making  them useful  as
ointment  bases.  Solid  grades  are  generally  employed  in  topical  ointments,  with  the
consistency of the base being adjusted by the addition of liquid grades of polyethylene glycol.
Mixtures of polyethylene glycols can be used as suppository bases, for which they have many
advantages over fats. For example, the melting point of the suppository can be made higher to
withstand exposure to warmer climates; release of the drug is not dependent upon melting
point; the physical stability on storage is better; and suppositories are readily miscible with
rectal fluids. Polyethylene glycols have the following disadvantages: they are chemically more
reactive than fats; greater care is needed in processing to avoid inelegant contraction holes in
the  suppositories;  the  rate  of  release  of  water-soluble  medications  decreases  with  the
increasing molecular weight of the polyethylene glycol; and polyethylene glycols tend to be
more irritating to mucous membranes than fats. Aqueous polyethylene glycol solutions can be
used either as suspending agents or to adjust the viscosity and consistency of other suspending
vehicles. When used in conjunction with other emulsifiers, polyethylene glycols can act as
emulsion stabilizers.
Liquid polyethylene glycols are used as water-miscible solvents for the contents of soft
gelatin  capsules.  However,  they may cause  hardening of  the capsule shell  by preferential
absorption of moisture from gelatin in the shell. In concentrations up to approximately 30%
v/v, PEG 300 and PEG 400 have been used as the vehicle for parenteral dosage forms. In
solid-dosage  formulations,  higher-molecular-weight  polyethylene  glycols  can  enhance  the
effectiveness  of  tablet  binders and impart  plasticity to granules.  However,  they have only
limited  binding  action  when  used  alone,  and  can  prolong  disintegration  if  present  in
concentrations greater than 5% w/w. When used for thermoplastic granulations, a mixture of
the powdered  constituents  with  10–15% w/w PEG 6000 is  heated  to  70–750C. The mass
becomes paste like and forms granules if stirred while cooling. This technique is useful for the
preparation  of  dosage  forms  such  as  lozenges  when  prolonged  disintegration  is  required.
Polyethylene  glycols  can  also  be  used  to  enhance  the  aqueous  solubility  or  dissolution
characteristics of poorly soluble compounds by making solid dispersions with an appropriate
polyethylene glycol. Animal studies have also been performed using polyethylene glycols as
solvents for steroids in osmotic pumps. In film coatings, solid grades of polyethylene glycol
can be used alone for the film-coating of tablets or can be useful as hydrophilic polishing
materials. Solid grades are also widely used as plasticizers in conjunction with film-forming
polymers.  The presence of polyethylene glycols  in film coats,  especially of liquid grades,
tends  to  increase  their  water  permeability  and  may  reduce  protection  against  low pH  in
enteric-coating  films.  Polyethylene  glycols  are  useful  as  plasticizers  in  microencapsulated
products to avoid rupture of the coating film when the microcapsules are compressed into
tablets.
Polyethylene glycol grades with molecular weights of 6000 and above can be used as
lubricants,  particularly  for  soluble  tablets.  The  lubricant  action  is  not  as  good  as  that  of
magnesium stearate,  and stickiness may develop if the material becomes too warm during
compression.  An  antiadherent  effect  is  also  exerted,  again  subject  to  the  avoidance  of
overheating. Polyethylene glycols have been used in the preparation of urethane hydrogels,
which  are  used  as  controlled-release  agents.  It  has  also  been  used  in  insulin-loaded
microparticles for the oral delivery of insulin; it has been used in inhalation preparations to
improve aerosolization; polyethylene glycol nanoparticles have been used to improve the oral
bioavailability of cyclosporine; it has been used in selfassembled polymeric nanoparticles as a
drug carrier; and copolymer networks of polyethylene glycol grafted with poly(methacrylic
acid) have been used as bioadhesive controlled drug delivery formulations.
4.4.7. Poly Vinyl Pyrolidone:
Synonyms:
          Povidone, polyvidone
Chemical name:  
          1-Vinyl-2-pyrrolidinon-Polymere
Functional category: 
           Binder For pharmaceutical products, viscosity increasing agent, 
Description:    
           Fine white amorphous powder which precipitates readily
Chemical structure:
Molecular mass:
          2.500 - 2.5000.000 g·mol−1
Viscosity:    42000cps
Grades:
Depending up on the cross linking agent, cross linked PVP is divided into three grades 
Table 3: Grades of PVP
Cross linked PVP 0.45% 0.20% 1.0%
Viscosity 42000cps 21000cps 6200cps
Nitrogen% 12.3 12.3 12.3
   Water% 1.17 0.85 0.44
Melting point:   110-1800C
 Density:   1.2g/cm3
 Applications:
 PVP  is used as a binder  in many pharmaceutical tablets
 PVP is also used in personal  care products, such as shampoos and toothpastes,  in
paints, and adhesives. It has also been used in contact lens solutions and in hair sprays
and hair gels
 PVP is a stabilizer and has E number E1201. PVPP is E1202. It is also used in the
wine industry as a fining agent for white wine.
4.4.8. Magnesium Stearate:
 Nonproprietary Names:
                  BP            : Magnesium stearate
                  JP             : Magnesium stearate
                 PhEur    : Magnesii stearas
                 USP         : Magnesium stearate
Structure:
Synonyms:
Magnesium  octadecanoate;  stearic  acid  magnesium  salt;  octadecanoic  acid,
magnesium salt.
Chemical Name 
Octadecanoic acid magnesium salt 
 Empirical Formula :     
          C36H70MgO4          
Structural Formula:  
     [CH3(CH2)16COO]2Mg
Functional Category:
      Tablet and capsule lubricant.
Description:
Magnesium stearate is a fine, white, precipitated or milled, impalpable powder of
low bulk  density,  having  a  faint  odor  of  Stearic  acid  and  a  characteristic  taste.  The
powder is greasy to the touch and readily adheres to the skin.
Typical Properties:
Crystalline  forms:  high  purity  magnesium  stearate  has  been  isolated  as  a
trihydrate, a dihydrate, and an anhydrate.
Density (bulk): 0.159 g/cm3
Density (tapped): 0.286 g/cm3
Flash point: 250°C
Flow ability: poorly flowing, cohesive powder.
Melting range: 117-150°C (commercial samples) 
   126-130°C  (high purity magnesium stearate).
Stability and Storage Conditions:
Magnesium stearate is stable and should be stored in a well-closed container in a
cool, dry place.
Incompatibilities:
Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin,
some vitamins, and most alkaloidal salts.
Safety
Magnesium stearate is widely used as a pharmaceutical excipient and is generally
regarded as being nontoxic following oral administration.
Applications :
Magnesium  stearate  is  widely  used  in  cosmetics,  foods,  and  pharmaceutical
formulations.  It  is  primarily used as  a  lubricant  in capsule  and tablet  manufacture  at
concentrations between 0.25-5.0%. It is also used in barrier creams.
4.4.9. ISO PROPYL ALCOHOL:
Non proprietary Name 
              USP- Isopropyl alcohol 
              BP- Isopropyl alcohol
Functional Categories 
              USP-Solvent
              Other-Local disinfectant.
Synonyms
              Isopropanol, alcohol Isopropylieum, petrohol, dimethylcarbinol, 2-propan-2-ol,
secondary propyl alcohol.
Chemical Name 
              2-propranol.
Emperical formula
              C3H8O
Molecular formula
              60.1g/ml.
Description
Transparent,  colorless,  mobile,  volatile,  flammable liquid with a characteristic,
spirituous odor resembling that of a mixture of ethanol and acetone and a slightly bitter
taste.
Melting point
              88.50C  
Stability and storage condition
              Store in a tight container remote from heat and protected form light.
Incompatibilities
              Oxidizing agents like hydrogen peroxide and nitric acid decompose isopropyl
alcohlol. It may be slated out form aqueous mixtures by the addition of sodium chloride,
sodium sulfate and other salts or by sodium hydroxide.
Applications in Pharmaceutical Formulation
              Isopropyl alcohol can be used for pre-operative and skin cleaning and as a
disinfectant.
Other uses ingredient in lotions but as marked degreasing properties may limit its
usefulness in preparations used repeatedly.
5. METHODOLOGY
5.1 Innovator product evaluation
The  project  was  initiated  with  innovator  product  characterization.  Procured
innovator  product  FLOMAXTRA  XL  was  evaluated  for  physical  and  chemical
parameters. 
5.2 Preformulation Studies
Preformulation testing is an investigation of physical and chemical properties of a
drug substance alone and when combined with excipients. It  is the first in the rational
development of dosage forms.
The use of Preformulation parameters maximizes the chances in formulating an
acceptable, safe efficacious and stable product.
Physical properties
For a drug substance to formulate into a dosage form, it is necessary to study the
physicochemical properties of the bulk drug. 
Determination of bulk density and tapped density 
Bulk density is the ratio of the weight of a powder to the volume it occupies. It is
expressed as gm/ml. Volume occupied by powder includes volume of the solid portion of
the particle and voids between the particles. Bulk density is important in determining the
size of the containers needed for handling and processing
           An accurately weighed quantity of the powder (W), was carefully poured into the
graduated cylinder and the volume (Vo) was measured, then the graduated cylinder was
closed with lid, set into the density determination apparatus. The density apparatus was
set for 500 taps and after that, the volume (Vf) was measured and continued operation till
the two consecutive readings were equal. 
The bulk density, and tapped density were calculated using the following formulas:
Bulk density = W / Vo
Tapped density= W / Vf
Where,
W = weight of the powder
V0 = initial volume
Vf = final volume
a. Flow Properties:
           Irregular flow of powders from the hopper produces tablets with non uniform
weights.  As  respects  content  uniformity and  dose  precision  cannot  be  achieved  in  a
production of tablets & capsules.  Flow properties depend on particle size shape porosity
and density of bulk powder. The flow characteristics are measured by angle of repose
b. Angle of Repose:
Improper flow of powder is due to frictional forces between the particles.  These
frictional forces are quantified by angle of repose.
Angle of repose is defined as the maximum angle possible between the surface of
a pile of the powder and the horizontal plane.
                                       
Where, h = height of pile; r = radius of the base of pile; θ = angle of repose.
Lower the angle of repose better the flow property though the irregular surface of
the  particles  gives  higher  angle  of  repose.   It  can  be  decreased  by  the  addition  of
lubricants,  of  low concentration  decreases  the  angle  of  repose  at  high  concentration;
enhances angle of repose.
Fines (passed through mesh 100) increases angle of repose. 
Method: A glass funnel is held in place with a clamp over a glass plate, powder was
poured in funnel keeping the orifice blocked.   When powder is emptied from funnel,
angle of heap to horizontal plane is measured with protector. Height of pile (h) and radius
of the base (r) is measured with ruler. Thus the angle of repose is measured.
           tan θ =
h
r
Table 4:   Relationship between angle of repose (θ) & powder flow
c. Compressibility Index:
Compressibility is indirectly related to the relative flow rate,  cohesiveness and
particle size of a powder. 
Table 5: Compressibility Index Range
S. No. % compressibility index  Flow ability
      1 5-15 Excellent
      2 12-16 Good
      3 18-21 Fair-passable
4 23-35 Poor
      5 33-38 Very poor
      6 <40 Very Very Poor
    
    
Compressibility index were calculated using the formula:
S. No
Angle of repose (θ) 
degrees
Flow
1 < 25 Excellent
2 25-30 Good
3 30-40 Passable
4 40 & above Very poor
                                  Compressibility index= T.D-B.D/T.Dx100
d. Hausner Ratio:
    It  indicates the flow property of the powder and measured by the ratio of tapped
density to bulk density
Table 6:Hausner Ratio
                                      
Hausner ratio=T.D\B.D
                        Where,   T.D= Tapped density, B.D= Bulk density
Hausner ratio Properties
0 -1.2 Free flowing
1.2 -1.6 Cohesive powder 
e. Drug-Excipient Compatibility Study:
For drug-excipient compatibility study, selected excipients are as below
Table 7: List of excipients
S.No Excipient Functional category
1 Di-TAB Diluent
2 Lubritab Polymer
3 Eudragit RLPO Polymer
4 Eudragit L100 Polymer
5 Poly ethylene glycol 20000 Polymer
6 Stearic Acid Polymer
7 Povidone Binder
8. Magnesium stearate Lubricant
The compatibility study was carried out to study the possible interactions between
the  active  pharmaceutical  ingredients  and  several  inactive  ingredients  used  in  the
formulations and the ratio of Drug: Excipients was selected on the basis of the level of
excipients will be used in the formulation trials in their highest concentration. Physical
mixtures were kept in 40oC / 75% RH and 60oC in a 2ml glass vial in exposed condition
for 1 month.
Samples were withdrawn at 2nd and 4th week interval and observed for any change
in physical appearance. 
f. Fourier Transform Infrared Spectroscopy (FTIR)
Potassium Bromide (KBr) pellet method was employed. KBr was dried in oven at 45 °C
before analysis. The sample was triturated with KBr and pellet was prepared by setting
the pressure to 100 kg/cm2 for 2 minutes. The obtained pellet was analyzed in FTIR 8400
S,  Shimadzu,  Japan.  KBr  background  was  obtained  initially  before  analysis  of  test
samples. Test samples were analyzed following the same method.
Fig. 3:  Manufacturing Process
5.3 FORMULATION DEVELOPMENT:
a. Sifting
Accurately weigh required quantity of dry mix materials and sift through ASTM
30 mesh.
b. Dry mixing
Dry mix the materials geometrically in RMG for 5 minutes.
c. Binder solution
Dissolve  Tamsulosin  Hydrochloride  and  Povidone  in  required  quantity  of
Isopropyl alcohol with the aid of Mechanical stirrer. 
d. Granulation 
To the dry mix add the binder solution using the impeller speed of 150 rpm and
the chopper at 1500 rpm for 3 minutes in RMG. 
e. Drying 
Dry the granulated mass at inlet temperature of 45oC ±5oC in tray drier to get
LOD in the range of 0.5 –1.0%w/w at 50oC using moisture analyzer
f. Size reduction
Reduce the size of the dried granules in Multi mill at medium speed and knife 
forward direction using 1.5mm Mesh. 
g. Lubrication 
            Lubricate the sized granules with magnesium stearate for 5 minutes.
h. Compression
            Compress the lubricated blend with the following specifications
Table 8: Compression specifications
Description White biconvex shaped tablets
Tooling 8.99 ×6.51 Oval shaped
Hardness 60-75N
Thickness 3.40-4.20mm
Friability NMT 1% w/w
Uniformity of Weight ± 5% of average weight
        
Table 9: FORMULATION TRIALS
Ingredients
mg/tablet
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 Trial 6 Trial 7 Trial 8 Trial 9
Trial 
10
Dry Mixing
Di Tab 154.6 184.6 194.6 189.6 179.6 184.6 184.6 159.6 172.8 163.9
Eudragit 
RSPO 50 30 25 30 30 35 40 40 40 0
Lubritab 10 10 10 10 10 10 10 10 10 10
Eudragit 
RLPO 0 0 0 0 20 10 5 0 0 40
Eudragit L100 0 0 0 0 0 0 0 0 0 25
PEG 20000 0 0 0 0 0 0 0 30 15 0
Binder Solution
Povidone 3 3 3 3 3 3 3 3 3 3
Tamsulosin 
Hydrochloride 0.404 0.404 0.404 0.404 0.404 0.404 0.404 0.404 0.404 0.404
Stearic acid 0 0 0 0 0 0 0 0 1.8 0
Isopropyl 
alcohol q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
Lubrication
Magnesium 
Stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1.2
Eudragit 
RSPO 0 0 0 0 0 0 0 0 0 0
Eudragit 
RLPO 25 15 10 10 0 0 0 0 0 0
Film Coating
Opadry white 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5
Purified water q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
Weight of 
tablet 250.0 250.0 250.0 250.0 250.0 250.0 250.0 250.0 250.0 250.0
5.4 Evaluation of Tablets:       
The following parameters were performed
a. Size and Shape:  
               The size and shape of tablets can be dimensionally described, monitored, and
control.  The compressed tablet’s  shape and dimensions are determined by the tooling
during compression process.
b. Weight Variation Test
The test ensures that  all the tablets in each batch are of same potency,  within
reasonable limits. According to the USP weight variation test, 20 tablets were weighed
individually  and  collectively.  Average  weight  per  tablet  was  calculated  from  the
collective weight.  Then the weights  of the individual  tablets were compared with the
average weight to determine weight variation. The specification of weight variation limits
as per USP is given in following Table.
Table.10: Specifications for weight variation of tablets as per USP
              The thickness of a tablet was the only dimensional variable related to the
process.10 tablets were measured for their thickness and diameter with Vernier calipers.
Average thickness and diameter were calculated. 
d. Hardness:
Average weight of tablet % Deviation
130 mg or less ± 10
More than 130 mg but less than 324 mg ± 7.5
324 mg or more ± 5
                Tablet hardness has been defined as the force required breaking a tablet in a
diametric compression test. To perform this test, there is a Tablet Hardness is present
which is manufactured by ERWEKA. The tablet is placed between two anvils, force is
applied to  the anvils  and the crushing strength  that  just  causes  the tablet  to break is
recorded. Hardness is thus sometimes termed as the tablet crushing strength.
e. Friability:
         The friability of tablets is determined by ERWEKA. 20 tablets were taken and
weighed. After weighing the tablets were placed in the friabilator and subjected to the
combined effects of abrasion and shock by utilizing a plastic chamber that revolves at 25
rpm for 4 minutes dropping the tablets from a distance of six inches with each revolution.
After operation the tablets were dedusted and reweighed. Friability is determined by
                                                F=100 (1-W0/Wt)
                           Where, W0 = Wt of tablets before friability test.
                                        Wt   = Wt of tablets after friability test.
g. Assay by HPLC
Ten tablets were finely powdered; quantities of the powder equivalent to 0.4 mg
of Tamsulosin Hydrochloride were accurately weighed, transferred to a 50 ml volumetric
flask containing 20 ml of methanol and allowed to stand for  30min with intermittent
sonication to ensure complete solubility of the drug. The mixture was made up to volume
with methanol. Filter the solution through 0.45µ nylon membrane filter. The solution was
suitably diluted and the absorption was determined by UV-detector in HPLC at λmax
225nm. The drug concentration was calculated from the below formula.
Where,
At=Absorbance of sample
AS=absorbance of standard
Ws= weight of working standard in drug in mg
Wt=weight of sample in mg
P= Potency of Tamsulosin Hydrochloride working standard.
g. Uniformity of dosage units
Uniformity of dosage units is defined as the degree of uniformity in the amount of drug
substance in each unit. As per USP uniformity of dose units was performed Table for
Application of content uniformity (CU) and weight variation test (WV) for tablet dosage
form USP was presented below.
Table 11: Uniformity of dosage units
Dosage form Type Subtype
Dose and Ratio of
drug substance
TABLETS
≥ 25 mg & 
≥25%
< 25mg or   <
25%
Uncoated ---- WV CU
Coated Film coated WV CU
Others CU CU
Uniformity of dosage units performed by content uniformity method because percentage
of drug is less than 25mg
h.Dissolution 
Method of analysis for Tamsulosin Hydrochloride tablets 0.4mg    
Methodology: 
The Dissolution method adopted for analyzing the tablets was as per the current
USP Monograph for Tamsulosin Hydrochloride Capsules. 
Invitro dissolution Studies:
 Preparation of pH 2.0 solution: 
              Dissolve 8.7 ml of perchloric acid in 1900 ml of water. Adjust with 2.0N 
Sodium hydroxide solution   to a pH of 2.0, and add sufficient water to make 2000 ml. 
Filter the solution through  0.45µ membrane filter. 
 Preparation of Mobile Phase:
 Prepare a filtered and degassed mixture of pH 2.0 solution and Acetonitrile in the 
ratio 1400:600.
Chromatographic Conditions:
 Column                       : Inertsil ODS 3V, 150 x 4.6 mm, 5 µm.
 Flow rate           : 1.5ml/min.
 Detector                       :  UV,225 nm
 Column temperature            :    40°C
Injection volume           :  100µl 
Run time                        : 15 minutes
1. Acid stage:
Dissolution Parameters:
  Medium   : 500 ml of Acid stage medium
 Apparatus : USP Type-II (Paddle)
 RPM : 100
 Temperature  : 37 ± 0.5°C 
 Time intervals : 2nd hr
Preparation of acid stage medium:
Dissolve 2.0 g of sodium chloride in 5.7 ml of hydrochloric acid, and add water to
make up to 1000 ml.
 Preparation of Polysorbate 80 solution: 
Take 3.0g of Polysorbate 80 into a 200 ml of volumetric flask, add 150 ml of 
water and sonicate to dissolve and dilute to volume with water.    
Preparation of diluent:
 Prepare a mixture of water and acetonitrile in the ratio 70:30.
 Preparation of Standard Solution: (Acid stage standard)
 Weight accurately about 50 mg of Tamsulosin Hydrochloride working reference
standard transfer 100 ml volumetric flask add 70 ml of diluent, sonicate to dissolve the
content and make up to the mark with diluent. Transfer 2 ml of above solution into a 50
ml volumetric flask and make up to the mark with acid stage medium.
Transfer 2 ml of above solution into a 50 ml volumetric flask and make up to the 
mark with acid stage medium. Filter the solution through 0.45µ membrane filter.
Procedure:    
Set  the  parameters  of  dissolution  apparatus  as  mentioned  above,  Transfer  the
tablets in to an each of the six dissolution jars, run the apparatus and immediately add 1
ml of  polysorbate 80 solutions into each dissolution jar.  After  completion of 2 hours
withdrawn 15 ml of the sample solution from each dissolution jars.  Filter the solution
through 0.45µ membrane filter. 
Separately inject 100µL of dissolution media, five replicate injections of standard 
solution and single injection of Sample solutions into the chromatograph, record the 
chromatograms and measure the peak responses. 
System Suitability:
Chromatograph the standard preparation and sample preparation record the peak
responses. The relative standard deviation for five replicate standard solution injections is
not more than 2.0%. 
The tailing factor of peak should be not more than 2.0 and the theoretical plates of
peak should be not less than 2000.
Calculation:
% Labeled amount of Tamsulosin Hydrochloride dissolved at the end of the 2nd hr
(D2 acid stage) in Acid stage medium.
  AT1        WS1          2            2          500                    P                            
-------x----------x--------x---------x --------x ----------------------
  AS1       100          50          50            1         Label claim in mg
Where,
AT1  = The area of the Tamsulosin Hydrochloride peak in sample solution.
As1 = The Average area of the Tamsulosin Hydrochloride peak in standard solution.
Ws1 = Weight of the Tamsulosin Hydrochloride working standard taken in mg
P     = Potency of the Tamsulosin Hydrochloride working standard used (on as is basis).
2. Buffer stage:
Dissolution Parameters:
Medium   : 500 ml of pH 7.2 Phosphate Buffer 
Apparatus : USP Type-II (Paddle)
RPM : 100
Temperature  : 37 ± 0.5°C 
Time intervals: 4, 6, 8, 12, 16, 20, 24 and 30 hr
Preparation of 0.5N Hydrochloric Acid Solution:
Mix 41.5 ml of Hydrochloric Acid (35%) in 1000 ml of water.
Preparation of pH:7.2 Phosphate Buffer:
Dissolve 6.8 gms of Potassium hydrogen orthophosphate and 0.8 gms of sodium
hydroxide in 1000 ml of water and adjust the pH 7.2±0.05 with 2N Sodium Hydroxide
Solution.
Preparation of Standard Solution: (Buffer stage standard)
Weight accurately about 50 mg of Tamsulosin Hydrochloride working reference
standard transfer 100 ml volumetric flask add 70 ml of diluent, sonicate to dissolve the
content and make up to the mark with diluent. Transfer 2 ml of above solution into a 50
ml volumetric flask and make up to the mark with buffer stage medium.
Transfer 2 ml of above solution into a 50 ml volumetric flask and make up to the
mark with buffer stage medium. Filter the solution through 0.45µ membrane filter.
Transfer the 10 ml of above solution into a test tube containing 1.0 ml of 0.5N
Hydrochloric acid and mix well. Filter the solution through 0.45 µ nylon filters.
Preparation of Sample solution:
After completion of the dissolution in acid stage medium, drain the solution from
each jar. Add about 500 ml of pH 7.2 Phosphate buffer previously maintained at 37  ±
0.5°C into each dissolution jar and run the apparatus. At the end of the specified time
interval withdrawn 15ml of the sample solution from each dissolution jar and replace the
equal volume of dissolution medium previously maintained at 37 ± 0.5°C. 
Transfer the 10 ml of above solution into a test tube containing 1.0 ml of 0.5N
Hydrochloric acid and mix well. Filter the solution through 0.45 µ nylon filters.
Procedure: 
Separately inject 100µL of dissolution media, Five replicate injections of standard
solution  and  single  injection  of  Sample  solutions  into  the  chromatograph,  record  the
chromatograms and measure the peak responses. 
System Suitability:
Chromatograph the standard preparation and sample preparation record the peak
responses. The relative standard deviation for Five replicate standard solution injections
is not more than 2.0%. 
The tailing factor of peak should be not more than 2.0 and the theoretical plates of
peak should be not less than 2000.
Calculation:
%  Labeled  amount  of  Tamsulosin  Hydrochloride  dissolved  at  respective  time
intervals (Dn)
  AT2        WS1          2       2         500                 P                              
-------x----------x------x-------x -------x --------------------- x100 
  AS1         100         50    50         WT      Label claim in mg     
Where,
AT2  = The area of the Tamsulosin Hydrochloride peak in sample solution.(Buffer stage 
           sample)
As1 = The Average area of the Tamsulosin Hydrochloride peak in standard solution.
Ws1 = Weight of the Tamsulosin Hydrochloride working standard taken in mg
WT = Weight of the Tamsulosin Hydrochloride pellets taken in mg
P     = Potency of the Tamsulosin Hydrochloride working standard used (on as is basis).
RESULTS AND DISCUSSION 
6.  RESULTS AND DISCUSSION
6.1 Standard Graph of Tamsulosin Hydrochloride 
Table 12: Construction of Standard Graph of Tamsulosin Hydrochloride 
     CONCENTRATION(µg/ml)
                       
PEAK AREA
20 36782
40 73160
80 141534
120 220216
160 293103
200 376210
240 440213
                          Fig. 4: Standard Graph of Tamsulosin Hydrochloride
6.2 Innovator Product Evaluation
Flomaxtra  XL  is  a  successful  brand  tablet  formulation  of  Tamsulosin
Hydrochloride in European market, manufactured by Astellas pharma ltd was selected as
the reference product to the present work. The physico-chemical parameters with respect
to Flomaxtra XL like thickness, hardness, dissolution rate were evaluated. 
Innovator product evaluation 
Brand name :  FLOMAXTRA XL
Label Claim : Each film coated tablet contains tamsulosin hydrochloride 0.4mg
Mfg. by :  Astellas pharma ltd, Europe
Physical Parameters:
 Description:
Round, bi-convex, yellow, film-coated tablets debossed with the code '04'
1. Average weight : 250 mg
2. Dimensions : 9.00 mm
3. Thickness : 4.60 - 4.62 mm
4. Hardness :  100 -110N.
  Table 13: Dissolution profile for Flomaxtra XL
Time (hrs)
% Tamsulosin
Hydrochloride
released
2 17.2
4 29.5
6 40.9
8 51.8
12 65.1
16 75.2
20 84
24 90.2
30 91.9
The dissolution profile of innovator product was considered as the standard   to compare
the dissolution profiles of the present formulations. 
6.3 Preformulation studies:
Preformulation Characteristics of final blend of all Formulation were given below:
Table 14: Preformulation study of lubricated Blend 
Trial 
Bulk
Density
g/cm³
Tapped
Density
g/cm³
Hausner
Ratio
Compressibility
Index (%)
I=1-V0/V
Angle of
Repose
( º )
1 0.56 0.65 1.16 13.84 27.5
2 0.54 0.63 1.16 14.28 26.8
3 0.53 0.62 1.15 14.51 26.5
4 0.52 0.60 1.15 13.5 27.8
5 0.53 0.61 1.15 13.1 27.6
6 0.58 0.63 1.14 14.6 26.9
7 0.55 0.66 1.16 14.32 26.6
8 0.51 0.60 1.15 13.55 27.4
9 0.59 0.69 1.14 13.67 27.8
10 0.55 0.62 1.15 14.1 27.6
The above results indicate that all the final lubricated blends have good flow property and
compressibility. 
6.4. Evaluation of Tamsulosin Hydrochloride Sustained Release tablets
a. Weight variation: 
20 intact tablets are selected randomly, individual weights and average weight of
the tablets is determined. The result of all the batches were found to be satisfactory and
meeting the acceptance criteria. 
b. Assay by HPLC
The assay results of Tamsulosin Hydrochloride sustained release tablets are given
below.  The  assay  values  are  between  90% to  110%.  All  the  tablets  are  within  USP
specification limit.
Table 15.Percentage Drug Content
S No Formulation %Drug Content
1 Trial 1 96.5 ± 0.2
2 Trial 2 97.7 ± 0.3
3 Trial 3 98.1 ± 0.2
4 Trial 4 95.5 ± 0.4
5 Trial 5 97.3 ± 0.3
6 Trial 6 95.7 ± 0.4
7 Trial 7 98.2 ± 0.2
8 Trial 8 100.1± 0.3
9 Trial 9 99.8± 0.2
10 Trial 10 100.2± 0.3
C. Uniformity of dosage units
            10 intact tablets are selected randomly, weighed and analyzed for drug
individual  tablets  drug  content.  The  result  of  all  the  batches  were  found  to  be
satisfactory and meeting the acceptance criteria as per USP. All the batches L1 values
were less than 15. 
6.5 COMPATABILITY STUDIES:
Table. No 16: Compatibility study of drug and excipients:
S. No. Drug and Excipients Initial PhysicalDescription
25°C / 60% RH
&   40°C / 75% RH (Closed)
1st Week 2nd Week 4th Week
1 Tamsulosin Hydrochloride White crystalline powder * * *
2 Tamsulosin Hydrochloride 
+ DITAB Off-white powder * * *
3 Tamsulosin Hydrochloride+Eudragit RSPO white powder * * *
4
Tamsulosin 
Hydrochloride+Eudragit 
L100
White powder * * *
5 Tamsulosin Hydrochloride+Eudragit RLPO White powder * * *
6 Tamsulosin Hydrochloride 
+ Lubritab
white powder 
contain crystalline 
material
* * *
7 Tamsulosin Hydrochloride+ Povidone Off-white powder * * *
8 Tamsulosin Hydrochloride +Isopropyl alcohol Off-white thick mass * * *
9  Tamsulosin Hydrochloride 
+  Purified Water
Off-white thick 
mass.
* * *
Note: Star mark (*) indicates that there is no interaction between drug and excipients at
25°C/60% RH, 40°C/75% RH.
OBSERVATION:  The drug excipient compatibility study was performed based on ICH
guidelines in various stress conditions like 25°C/60%RH and 40°/75%RH, for a period of
1 month, there was no interaction found during the study period.
Fourier Transform Infrared Spectroscopy (FTIR):
The FTIR was carried out between drug and the polymers physical mixtures. The
FTIR was carried out on the Tamsulosin Hydrochloride and Lubritab,   Eudragit L100,
Eudragit  RLPO. The results obtained by the physical  mixtures are compared with the
standard graph and the results showed that there occurs no incompatibility with the drug
and the excipients. The study was carried out for final  confirmed formulation and the
results are being compared with the standard drug.
Fig. 5: IR Report of Pure Tamsulosin Hydrochloride drug
              
     Fig.6: IR Report of Physical Mixture of Tamsulosin Hydrochloride with Eudragit
RLPO
             Fig.7: IR Report Of Physical Mixture Of Tamsulosin Hydrochloride with
EudragitRSPO
6.6 Formulation development        
The originator product “Flomaxtra XL” formula was protected by the patents and
use of different polymeric matrices in connection with working formula.
As “Flomaxtra XL” was selected as the reference product and the efforts were
continued towards development with different polymers as a Primary choice that need to
evaluate. Polymer controls drug release followed by dissolution, initiates the solubility
process and its selection reflects the behavior of the drug in vitro and in vivo.
The most widely used polymers like Eudragit RSPO, Eudragit RLPO, Eudragit
L100, Lubritab were  subjected to the  present formulation development of  Tamsulosin
Hydrochloride and the best opted polymer was identified on trial and error basis and with
the scope of Non-infringement.
Different trials were attempted by incorporating various polymers like Eudragit
RSPO, Eudragit RLPO, Eudragit L100 and Lubritab. Dissolution tests were carried for
the prepared test formulations (trail 1 to trail 10) with the parameters as per the current
version of USP Monograph for Tamsulosin Hydrochloride Capsules.
The results  of  dissolution studies  of  the formulation were  compared  to  the innovator
product dissolution profile.
 From  trial  1  to  4  Eudragit  RSPO  was  tried  at  different  concentration  with  the
combination of Lubritab intra granularly with extra granular RLPO. The results of all
the 4 trails suggested that in case of control in drug release at the initial hour resulted in
incomplete dissolution and whenever the drug was completely released the drug release
was faster  at the initial  stage and the results  of the trials  were not matching to the
reference Originator.
 In  trial  5  to  7,  RLPO was  also  used  along  with  above  matrix  as  intra  granular  at
different ratios without any extra granular addition and the drug release was incomplete
in these trials and drug release was not comparable to the Originator. 
 In trial 8 & 9, in place of RLPO, PEG 20000 was used along with RSPO and Lubritab
matrix as intra granular at different ratios without any extra granular addition of any
material  and  the  drug  release  in  case  of  control  in  at  the  initial  hour  resulted  in
incomplete dissolution and where the drug was completely released the drug release
was faster  at the initial  stage and the results  of the trials  were not matching to the
reference originator.
 In  trial 10, in place of RLPO/ PEG 20000, L 100 was used and in place of RSPO,
RLPO used along with Lubritab intra granular without any extra granular addition of
any material. The result of this batch was comparable to the originator profile matching
In-Vitro similarity factor.
 Hence from the all the above experiment trial 10 was selected as an ideal formulation.
      
Table no 17: Dissolution data for 10 trials:
                           (Time in hrs on X-axis Vs Percent drug release on Y-axis)
Time
in hrs T1 T 2 T 3 T 4 T 5 T 6 T 7 T 8 T 9 T 10
2
27.7
±0. 06
31.2
±0.02
40.9
±0.04
32.6
±0.11
24.6
±0.08
32.2
±0.09
27.9
±0.09
28.9
±0.09
40.6
±0.11
21.2
±0.06
4
45.2
±0.09
46.2
±0.13
51.3
±0.08
50
±0.09
36.9
±0.03
46.1
±0.12
41
±0.04
41.5
±0.07
57.9
±0.14
35.4
±0.09
6
51.9
±0.03
53.1
±0.12
58.1
±0.01
58.6
±0.07
42.8
±0.05
51.8
±0.03
45.5
±0.05
47.1±
0.09
65.2
±0.09
49.2
±0.06
8
57.9
±0.11
58.7
±0.14
64.6
±0.09
63.2
±0.05
46.8
±0.04
58.2
±0.08
50.4
±0.02
51.6±
0.13
69.9
±0.07
55.4
±0.04
12
64.6
±0.09
64.6
±0.02
74.6
±0.14
73.1
±0.1
51.3
±0.14
64
±0.09
57.1
±0.01
56.7
±0.14
78.9
±0.06
65.1
±0.08
16
69.7
±0.04
71.6
±0.1
82.3
±0.13
78.5
±0.03
56.4
±0.12
69.3
±0.14
63.7
±0.08
63.6
±0.12
83.8
±0.14
73.5
±0.06
20
74
±0.06
73.9
±0.12
90.6
±0.06
81.3
±0.08
61.0
±0.1
74.1
±0.5
68.4
±0.03
66.1
±0.08
87.0
±0.05
82.7
±0.04
24 77.7
±0.11
79.9
±0.04
101.2
±0.13
86.3
±0.11
65.5±
0.3
78.4
±0.1
74.8
±0.02
71.2
±0.2
88.1
±0.06
90.2
±0.08
30 82.6
±0.07
84.5
±0.03
---
88.3
±0.11
65.8
±0.2
81.4
±0.4
79.1
±0.01
76.7
0.14
89.9
±0.05
100.1
±0.09

                                   
Table.No:18 Dissolution Result of Trial 10
pH FLOMAXTRA XL TRIAL 10
pH 1.2 buffer, 500ml basket,100rpm
2hrs 17.2 21.2
pH 7.2 buffer, 500ml basket,100rpm
4 29.5 35.4
6 40.9 49.2
8 51.8 55.4
12 65.1 65.1
16 75.2 73.5
20 84 82.7
24 90.2 90.2
30 91.9 100.1
f1 6.05
f2 65.62
f1: Dissimilarity factor
f2: Similarity factor
Fig 9: comparison of Flomaxtra XL with trial 10
6.7 Stability study:
 For all the pharmaceutical dosage forms it is important to determine the stability
of the dosage form. This will include storage at both normal and exaggerated temperature
conditions, with the necessary extrapolations to ensure the product will, over its designed
shelf  life,  provide  medication  for  absorption  at  the  same  rate  as  when  originally
formulated.  The design of the formal  stability studies for  the drug product should be
based on the knowledge of the behavior and properties of the drug substance and formal
stability studies on the drug substance. Specification which is list of tests, reference to the
analytical procedures and proposed acceptance criteria, including the concept of different
acceptable criteria for release and shelf life specifications, is addressed in ICH CS L6AS
and IS6B.
Storage conditions 
Stability samples are stored at
Accelerated   : 40±2°C/75±5% RH
Intermediate: 30±2°C/65±5% RH
Long term     : 25±2°C/60±5% RH
             Testing Intervals for 
Accelerated: Initial, 1, 2, 3 & 6 months
Long term: Initial, 3, 6, 9, 12, 18, 24 & 36 months. 
Intermediate: Initial, 3, 6, 9 & 12 months.
The formula of F10 was optimized and selected for evaluation studies. Further stability
study was done for F10
Table No 19: Dissolution profile for trial 10 after stability studies(40±2°C/75±5%
RH)         (Time in hrs on X-axis Vs Percent drug release on Y-axis)
  
.              
Time Flomaxtra Trail 10
pH 1.2 buffer, 500ml basket,100rpm
2 17.2 23.4
pH 7.2 buffer, 500ml basket,100rpm
4 29.5 36.5
6 40.9 48.9
8 51.8 55.0
12 65.1 64.9
16 75.2 73.2
20 84 84.2
24 90.2 91.3
30 91.9 99.2
Fig. 10: Dissolution profile for trial 10 after stability studies(40±2°C/75±5% RH)
Table No.20 Dissolution profile for trial 10 after stability studies (30±2°C/65±5%
RH)            (Time in hrs on X-axis Vs Percent drug release on Y-axis)
Time        Flomaxtra XL Trail 10
pH 1.2 buffer, 500ml basket,100rpm
2 17.2 22.2
pH 7.2 buffer, 500ml basket,100rpm
4 29.5 35.9
6 40.9 49.5
8 51.8 54.9
12 65.1 64.8
16 75.2 73.5
20 84 83.6
24 90.2 91.8
30 91.9 98.7
Fig. 11: Dissolution profile for trial 12 after stability studies (30±2°C/65±5% RH)
Table  No.21 Dissolution profile  for trial  12 after stability  studies(25±2°C/60±5%
RH)          (Time in hrs on X-axis Vs Percent drug release on Y-axis)
Time Flomaxtra trail 10
pH 1.2 buffer, 500ml basket,100rpm
2 17.2 21.6
pH 7.2 buffer, 500ml basket,100rpm
4 29.5 35.5
6 40.9 47.2
8 51.8 53.4
12 65.1 65.1
16 75.2 74.1
20 84 81.9
24 90.2 91.6
30 91.9 99.3
Fig. 12:  Dissolution profile for trial 12 after stability studies(25±2°C/60±5% RH)
SUMMARY AND CONCLUSION
7. SUMMARY AND CONCLUSION
 The present work, an industrial project, entitled “Formulation and evaluation of
sustained release tablets of Tamsulosin Hydrochloride” was taken up in collaboration
with Rachem pharma Pvt. Ltd., Hyderabad. The literature review showed that the drug
Tamsulosin hydrochloride is an alpha adrenergic blocking agent used in the treatment of
benign prostatic hyperplasia.
The present work was aimed towards developing a sustained release oral dosage
form having Tamsulosin hydrochloride.
Before going to develop the formulation a detailed product literature review was
carried out to know the innovator product and the patent status of the drug.
Preformulation studies were conducted to check the drug polymer and excipients
compatibility and the results had confirmed compatibility among them.
As per the proto type evaluation results it was concluded that wet granulation is
the best possible method of granulation for the present work.
Granules were evaluated for tests like bulk density, tap density, compressibility
index before compression. 
Compressed  tablets  were  tested  for  in-vitro  drug  release  by  following  the
dissolution  parameters  mentioned  in  the  current  version  of  USP  Monograph  for
Tamsulosin Hydrochloride Capsules. From all the above studies it was concluded that
trial  10  which  has  Eudragit L100  and  Eudragit  RLPO in  the  ratio  of  1:1.6,  had
successfully  retarded  the  release  of  Tamsulosin  hydrochloride  for  30hrs  in  a  rate
controlled manner.
 Hence the present work suggests Eudragit L100 and Eudragit RLPO as suitable
rate retarding polymer for control release formulation of Tamsulosin hydrochloride and
the study recommends in vivo evaluation of the best optimized formula.
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